A new analysis shows that over the past 40 years, people in the U.S. diagnosed with cancer gained 14 million years of additional life thanks to the results of cancer clinical trials conducted by the National Cancer Institute’s (NCI’s) publicly funded National Clinical Trials Network (NCTN). The analysis was presented today at the annual meeting of the European Society for Medical Oncology (ESMO).
In total, the NCTN consists of four groups that research cancers in adults (Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network) and one group that performs research into childhood cancers (Children’s Oncology Group). These four encompass a network that runs clinical trials at more than 2,000 academic and community treatment sites across the U.S. and beyond.
In this study, researchers analyzed 163 randomized, phase III studies published from 1980 through 2019. Subsequently, they estimated life-year gains for the 128 trials that found either statistically significant improvement in overall survival time (n=91) or a trend to improved overall survival (n=37) for patients, and they mapped these gains.
The analysis found that through 2020 these trial results gave an additional 14.0 million years of life to people with cancer in the U.S. also found the published results of these NCTN studies have been cited more than 166,000 times, and that more than 80% of the studies influenced treatment guideline recommendations, demonstrating the profound scientific impact of these trials on cancer research and care over the decades.
.“Our study illustrates the many ways in which federally sponsored trials have benefitted the lives of cancer patients and the scientific field,” Unger said. “There are many, many new commonly used treatments available to patients that may never have come into practice without NCTN trials,” said SWOG biostatistician and health services researcher Joseph Unger, PhD, of the Fred Hutchinson Cancer Research Center, led the analysis via a press release.
SWOG Group Chair Dr. Charles Blanke, senior author on the analysis, commented. “We have always known NCTN research profoundly benefited the lives of people affected by cancer,” Blanke said. “Dr. Unger’s work quantifies that benefit and demonstrates cooperative research is an incredibly low-cost, high-impact investment.”
“Dr Unger’s findings are all the more important in this time of increasing costs of clinical research,” said Peter J. O’Dwyer, MD, group co-chair of the ECOG-ACRIN Cancer Research Group and a co-author of the work. “The return to the American people of government-funded investment in better cancer care has been remarkably solid – a huge impact.”
And benefits from these NCTN trials are expected to continue to accrue.
“When we project estimates into the future, the estimates get larger very quickly,” Unger noted. In fact, the authors projected that by 2030, 23.4 million life years will have been gained based on the same set of trials.
— Bioengineer.org (@bioengineerorg) September 20, 2021
“The results from these cancer clinical trials reflect the experience of participants from both community and academic sites and show a dramatic gain in years of life,” said Dr. Meg Mooney, associate director of NCI’s Cancer Therapy Evaluation Program. “This work demonstrates the impact that cancer clinical trials conducted broadly on a national scale have on the field of cancer research and on people with cancer.”
— Teknocks (@teknocks) September 20, 2021